INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In TG Therapeutics, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

STEVENSON, Md.--()--The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of purchasers of TG Therapeutics, Inc. (Nasdaq: TGTX) (“TG Therapeutics” or the “Company”) common stock during the period between September 15, 2014 and October 12, 2016, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until March 7, 2017 to seek appointment as lead plaintiff.

If you wish to choose counsel to represent you and the Class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the Class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in TG Therapeutics common stock during the Class Period. Members of the Class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action.

The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period that TG Therapeutics had failed to implement a proper screening protocol in the GENUINE Phase 3 trial enrolling sites, that it was not enrolling patients at the required rate for the study to be completed on time, that it would never get 330 enrolled patients, and that a progression-free survival was not an achievable endpoint.

According to the complaint, following an October 13, 2016 announcement that the Company had filed with the U.S. Food and Drug Administration an amended protocol for the GENUINE Phase 3 trial eliminating part of the study and reducing target enrollment, the value of TG Therapeutics shares declined significantly.

If you have suffered a loss in excess of $100,000 from investment in TG Therapeutics common stock purchased on or after September 15, 2014 and held through the revelation of negative information during and/or at the end of the Class Period and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please visit our website at http://www.browerpiven.com/currentsecuritiescases.html. You may also request more information by contacting Brower Piven either by email at hoffman@browerpiven.com or by telephone at (410) 415-6616. Brower Piven also encourages anyone with information regarding the Company’s conduct during the period in question to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s. If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.

Contacts

Brower Piven, A Professional Corporation
Charles J. Piven, 410-415-6616
1925 Old Valley Road
Stevenson, Maryland 21153
hoffman@browerpiven.com

Contacts

Brower Piven, A Professional Corporation
Charles J. Piven, 410-415-6616
1925 Old Valley Road
Stevenson, Maryland 21153
hoffman@browerpiven.com